Table 3.
Comparison between relapse and non-relapse patients in a subgroup of 27 paediatric LS patients who completed the recommended course of systemic therapy (>2 years)
| Characteristics | Relapse (n=11) |
No Relapse (n=16) |
|
|---|---|---|---|
| Gender | n (%) | n (%) | p-value2 |
| Female | 8 (73) | 11 (69) | 1.00 |
| LS Subtype | |||
| Circumscribed Superficial | 1 | 5 | |
| Circumscribed Deep | 3 | 1 | |
| Generalized Morphea | 0 | 3 | |
| Linear Trunk/Limb | 6 | 0 | |
| Linear Face | 0 | 4 | |
| Mixed Morphea | 1 | 3 | |
| Pansclerotic Morphea | … | … | |
| Eosinophilic Fasciitis | … | … | |
| Laboratory Evaluation* | |||
| ANA Positive | 6 (55) | 4 (27) | 0.23 |
| ssDNA Positive | 5 (46) | 5 (33) | 0.69 |
| AHA Positive | 4 (36) | 8 (57) | 0.43 |
| CPK Elevated | 4 (36) | 5 (36) | 1.00 |
| Aldolase Elevated | 5 (45) | 2 (15) | 0.18 |
| Extracutaneous Manifestations | |||
| At least one ECM | 4 (36) | 8 (50) | 0.70 |
| Relapse mean (SD) |
No Relapse mean (SD) |
p-value | |
| Age Onset (years) | 11.34 (3.53) | 7.14 (3.51) | < 0.01 |
| Treatment Duration (mos) | 38.92 (15.67) | 44.99 (13.28) | 0.29 |
| Follow-up Duration (years) | 5.05 (1.89) | 5.72 (1.59) | 0.99 |
2
P-values were obtained using Chi-squared tests for categorical variables and Fisher exact tests when n<5 for a cell. Independent sample t-tests were used for continuous variables. P-values not provided for subtypes, as sample sizes were extremely low.
*
Laboratory parameters not obtained for all patients so denominators are provided
ANA (antinuclear antibody), ssDNA (single stranded DNA antibody), AHA (antihistone antibody), CPK (creatine phosphokinase)